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Abstract
Background: Autologous and allogeneic osteochondral grafts have been used to repair damaged or diseased cartilage.
There are drawbacks to both of these methods, however. Another possible source for osteochondral grafting is
photooxidized xenograft scaffolds. The purpose of this study was to evaluate the adaptive immune response to
unprocessed and photooxidized xenogeneic osteochondral grafts in a collagen-sensitive mouse model.
Methods: Unprocessed and photooxidized bovine and human osteochondral grafts were used. The grafts were
implanted subcutaneously in collagen-sensitive DBA/1LacJ mice for four or twelve weeks. ELISPOT assays were
conducted with spleen cells to evaluate the number of collagen-specific T cells that produce IL-2, IL-4, IL-5 or IFN-γ.
Serum was collected and ELISA assays were performed to determine the titers of collagen-specific and total IgG, IgG1,
IgG2a, or IgM antibodies. Histology was conducted on the retrieved osteochondral grafts.
Results: Results indicated that, with respect to adaptive T cell immunity, the photooxidized bovine grafts, unprocessed
human grafts and photooxidized human grafts did not induce a significant response to collagen. The unprocessed bovine
grafts, however, were slightly more immunogenic, inducing a weak immune response. With respect to antibody
production, the bovine grafts were less immunogenic than the human grafts. Bovine collagen-specific IgG antibodies were
not induced by these grafts, but production of IgM after twelve weeks was observed with both the unprocessed and
photooxidized bovine grafts. In contrast, photooxidized human osteochondral grafts induced IgG1 and IgG2a antibodies,
while the unprocessed human grafts did not. Pre-existing human collagen-specific IgM antibodies were present in all mice,
including sham-operated negative controls that did not receive an implant. Histological analysis revealed some degree of
fibrous encapsulation and inflammatory infiltrations in both bovine and human implants, whether unprocessed or
photooxidized.
Conclusion: Both bovine and human cartilage grafts showed weak, but clear immunogenicity in the DBA/1LacJ mice,
indicating that immunogenic collagen was still contained in the grafts, even after cleaning and photooxidation. The process
of photooxidation is still important in osteochondral grafting, since it stabilizes the surface of the cartilage by cross-linking
the collagen fibers, and allows for immediate load bearing and joint resurfacing.
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Symptomatic defects in the articular cartilage and under-
lying bone of various joints can result from different
means, including osteoarthritis, trauma and osteochon-
dritis dissecans. One accepted means of treatment is oste-
ochondral implantation, which has been used to treat
chondral and osteochondral defects of the femoral con-
dyle, talus, tibia, humeral capitulum and femoral head.
[1-3] Osteochondral Autograft Transplantation (OATS) is
a procedure that entails obtaining cylindrical osteochon-
dral grafts from a minimally weight-bearing portion of the
femoral condyles and transplanting them into an osteo-
chondral defect on the weight-bearing surface of a joint.
[2] There are concerns with using autogenous tissue for
osteochondral grafting. These include performing surgery
to harvest the grafts from an otherwise healthy joint [2]
and donor site morbidity [2,4]. The use of OATS is ideally
limited to smaller defects (1–4 cm2), to reduce donor site
morbidity. [1,2]
Grafting with osteochondral allografts has been used to
treat both small and large defects in various joints. [5-9]
There is concern, however, about the possibility of trans-
mitting viral diseases, such as human immunodeficiency
virus (HIV) and hepatitis, from donor to recipient when
implanting allogeneic tissue. [9,10] While the frequency
of transmission of viral diseases is low, the risk is never
completely removed. [10] Another concern is the poten-
tial for a host immune response to the donor tissue. [11-
13] Sirlin et al. [12] have demonstrated that there is a cor-
relation between an antibody response to osteochondral
allografts and increased inflammatory reaction associated
with less complete graft incorporation.
Another type of grafting material is osteochondral
xenografts. The concern with xenografts is rejection of the
graft by the recipient. Some work has been conducted in
the area of treating xenogeneic heart and vascular tissue to
make it more acceptable to the host, and this type of
processing may be applicable to orthopaedics. Xenoge-
neic pericardial tissue, which contains collagen, has been
treated by dye-mediated photooxidation in order to stabi-
lize the material. A study by Moore et al. [14] examined
bovine pericardial tissue treated by photooxidation and
found that the resultant tissue was resistant to chemical
and enzymatic digestion, maintained some of the physical
properties of natural pericardial tissue, and was more
resistant to in vivo degradation. Furthermore, analysis of
soluble bovine collagen that was treated by photooxida-
tion indicated crosslink formation. Subsequent studies
using photooxidized bovine pericardium [15,16] and por-
cine heart tissue [17-20] have confirmed these findings.
The photooxidized bovine and porcine tissues were also
found to be less immunogenic than untreated tissue.
[18,21]In vivo studies have suggested that the photooxi-
dized material shows potential for use in the replacement
of heart valves. [22-24] It should be noted, however, that
photooxidized tissue is not currently used clinically for
heart valve replacement. In vitro [25,26] and in vivo [27]
studies have also indicated that photooxidation can be
used to enhance the performance of vascular grafts.
Researchers have evaluated the efficacy of using photoox-
idation to improve the performance and acceptance of
osteochondral xenografts for the repair or replacement of
damaged articular cartilage. Akens et al. [28] conducted an
in vitro study to assess the interaction between photooxi-
dized bovine articular cartilage, untreated bovine articular
cartilage and synovial membrane. The authors concluded
that the photooxidized tissue may have a beneficial effect
on adjacent host cartilage. It should be noted, however,
that no viable chondrocytes were present in the photoox-
idized cartilage.
Several animal studies have been conducted on photoox-
idized osteochondral xenografts. [29-32] Kawalec et al.
[29] found that, after twelve weeks implantation of pho-
tooxidized bovine osteochondral grafts in the patellar
groove of rabbits, there was chronic inflammation and
active bone remodeling within the grafts. In several
instances, there was evidence of "bridging" between the
host bone and the margins of the implants. The cartilage
layer was intact and undamaged, and surrounded by a
thin layer of fibrous tissue. This finding was also observed
in a study by Nam et al., who evaluated osteochondral
autograft transplantation in a rabbit model. [33] Akens et
al. [30] implanted photooxidized bovine osteochondral
grafts into the femoral condyles of sheep and found that,
after twelve and eighteen months, there were fewer cystic
lesions in photooxidized xenografts, compared to
untreated xenografts and autografts. There was also evi-
dence of fusion between the photooxidized graft and host
cartilage, which was not observed with the other types of
grafts. At both twelve and eighteen months, a hyaline-like
cartilage matrix was observed for the photooxidized
xenografts. von Rechenberg et al. [31] found that pho-
tooxidation of osteochondral xenografts implanted in the
femoral condyles of sheep slowed down the rate of resorp-
tion in the subchondral bone of the grafts, due to the
decreased immunogenicity of the tissue. This led to
greater graft stability and improved the survival of the car-
tilage layer. In another study conducted by von Rechen-
berg et al. [32], the shape of the photooxidized
osteochondral graft was found to be important. Mush-
room-shaped grafts were associated with fewer cystic
lesions, less fibrous tissue, and more complete bone
remodeling, compared to cylindrical grafts. As in the pre-
vious study, the stability of the subchondral bone was sig-
nificant in the survival of the cartilage layer.Page 2 of 10
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tooxidized osteochondral xenografts, Hetherington et al.
[34] evaluated the innate immunological response in
humans towards osteochondral xenografts. Healthy
peripheral blood mononuclear cells were challenged with
antigens of bovine, porcine, ovine and equine origin that
had been partially or entirely treated by the photooxida-
tion process. Untreated bovine, porcine and equine spec-
imens resulted in a vigorous cytokine response. After the
first step in processing, which involved cleaning the spec-
imens in increasing strengths of ethanol, there was no sig-
nificant activation of cells of the innate immune system.
This lack of response continued through successive steps
of the process, including photooxidation. It was con-
cluded that processing of the osteochondral grafts dramat-
ically, if not completely, negated the immunostimulatory
properties of the test sample.
The long-term goal of this current research is to evaluate
the possibility of using photooxidized xeno-derived oste-
ochondral grafts as a repair matrix for damaged or dis-
eased cartilage. The graft is subjected to photooxidative
treatment because the process preserves the mechanical
integrity of the cartilage by cross-linking the collagen fib-
ers. It is presently unknown how this treatment affects the
acquired immunogenicity of the graft and hence its long-
term immune acceptance by the recipient. The purpose of
this study was to evaluate the adaptive cellular and
humoral immunologic response to unprocessed and pho-
tooxidized bovine and human osteochondral grafts in an
in vivo murine animal model.
Methods
Osteochondral grafts
The grafts used in this study were cylindrical plugs,
approximately 3.8 mm in diameter and 5 mm in length.
Each graft consisted of either bovine or human cartilage
with underlying bone. The bovine grafts used in the study
were obtained from the shoulder joint of the animal. They
were tested as either unprocessed (Bo-UP) or photooxi-
dized (Bo-P). The human grafts were obtained from a
bone bank and were taken from a cadaveric knee joint.
They were examined as either unprocessed (Hu-UP) or
photooxidized (Hu-P).
Photooxidation
After harvesting, the grafts were cleaned and rinsed thor-
oughly, to remove bone debris and marrow fat. Desig-
nated grafts were then subjected to the photooxidation
process. [14,19,30-32] Briefly, the grafts were submerged
in a 0.01% methylene blue solution in phosphate-buff-
ered saline (PBS) while exposed to a light source under
controlled conditions (light intensity, temperature, and
exposure time). After exposure, the photooxidized grafts
were rinsed and cleansed thoroughly in PBS to remove
excess methylene blue.
Table 1: Bovine experimental groups
BColl/CFA (n = 4 for comparison to 4-week groups) (n = 4 for 
comparison to 12-week groups)
Positive control; bovine collagen with complete Freund's adjuvant, 
euthanized 3 weeks after injection
BColl/IFA (n = 4 for comparison to 4-week groups) (n = 4 for 
comparison to 12-week groups)
Positive control; bovine collagen with incomplete Freund's adjuvant, 
euthanized 3 weeks after injection
Bo-UP-4 (n = 7) Unprocessed bovine graft, 4 weeks implantation
Bo-P-4 (n = 8) Photooxidized bovine graft, 4 weeks implantation
Bo-S-4 (n = 4) Negative control; sham operation, euthanized 4 weeks post-op
Bo-UP-12 (n = 8) Unprocessed bovine graft, 12 weeks implantation
Bo-P-12 (n = 8) Photooxidized bovine graft, 12 weeks implantation
Bo-S-12 (n = 4) Negative control; sham operation, euthanized 12 weeks post-op
B or Bo = bovine; UP = unprocessed; P = photooxidized; S = sham
Table 2: Human experimental groups
HColl/CFA (n = 8 for comparison to 4-week groups) (n = 4 for 
comparison to 12-week groups)
Positive control; human collagen with complete Freund's adjuvant, 
euthanized 3 weeks after injection
HColl/IFA (n = 8 for comparison to 4-week groups) (n = 4 for 
comparison to 12-week groups)
Positive control; human collagen with incomplete Freund's adjuvant, 
euthanized 3 weeks after injection
Hu-UP-4 (n = 8) Unprocessed human graft, 4 weeks implantation
Hu-P-4 (n = 8) Photooxidized human graft, 4 weeks implantation
Hu-S-4 (n = 4) Negative control; sham operation, euthanized 4 weeks post-op
Hu-UP-12 (n = 8) Unprocessed human graft, 12 weeks implantation
Hu-P-12 (n = 7) Photooxidized human graft, 12 weeks implantation
Hu-S-12 (n = 8) Negative control; sham operation, euthanized 12 weeks post-op
H or Hu = human; UP = unprocessed; P = photooxidized; S = shamPage 3 of 10
(page number not for citation purposes)
BMC Musculoskeletal Disorders 2006, 7:32 http://www.biomedcentral.com/1471-2474/7/32Experimental model
The animal model chosen for this study was the collagen-
sensitive DBA/1LacJ mouse (Jackson Laboratory, Bar Har-
bor, ME, USA). Grafts were implanted subcutaneously for
either four or twelve weeks. Each of the experimental mice
was first anesthetized with an anesthesia cocktail, and the
dorsum was shaved and swabbed with Betadine. A small
incision was created and an implant was inserted subcuta-
neously. The incision was then closed with nylon suture.
In addition to the experimental mice, several mice were
given a sham operation to serve as a negative control. As
additional controls, groups of mice were challenged with
bovine collagen as shown in Table 1, while others were
challenged with human collagen, as shown in Table 2.
The number of animals per group is also shown in Tables
1 and 2. The mice were cared for in accordance with the
guidelines of the OCPM Institutional Animal Care and
Use Committee.
At four or twelve weeks, blood was obtained from the tail
vein of mice from each group. The mice were then eutha-
nized with CO2 and the spleen cells were isolated for T cell
assessment.
Positive controls
Positive controls were established in this study, using
purified bovine type II collagen or human collagen
(Chondrex, Redmond, WA, USA) administered with
incomplete Freund's adjuvant (IFA) (Gibco BRL, Grand
Island, NY, USA) to induce a type 2 immune response.
Another set of mice received bovine or human collagen
administered with complete Freund's adjuvant (CFA) to
induce a type 1 immune response. The CFA was produced
by mixing inactivated M. tuberculosis H37RA (Difco Labo-
ratories, Detroit, MI, USA) at 1 mg/ml into IFA. The anti-
gens were mixed with adjuvants to a final concentration of
1 mg/ml. A total of 400 µl of antigen in either IFA or CFA
was injected intraperitoneally (IFA) or subcutaneously
(CFA). All positive controls were euthanized with CO2
three weeks after injection, and tested as described below.
ELISPOT assays
The frequency of collagen -specific T cells in the spleen
and the Th1/Th2 effector lineage of these cells were deter-
mined using cytokine ELISPOT by measuring collagen-
induced IFN-γ, IL-2, IL-4 and IL-5 production. ImmunoS-
pot® M200 plates (Cellular Technology Ltd., Cleveland,
OH) were coated overnight at 4°C with the different
cytokine-specific capture antibodies specified below. The
plates were then blocked with 1% bovine serum albumin
(BSA) in PBS for one hour at room temperature, and
washed four times with PBS. Subsequently, freshly iso-
lated spleens cells were plated at 106 cells per well, in two
to four replicate wells with or without the nominal anti-
gen or control antigens. The assay medium was serum-free
HL-1 (Biowhittaker, Walkersville, MD, USA) supple-
mented with 1 mM L-glutamine.
Following 24 hours (for IFN-γ and IL-2 measurements) or
48 hours (IL-4 and IL-5 measurements) of cell culture in
the incubator at 37°C, the cells were removed by washing
three times with PBS and then four times with PBS con-
taining 0.05% Tween-20 (PBST). The different bioti-
nylated detection antibodies specified below were added.
After overnight incubation at 4°C, the plates were washed
three times with PBST followed by incubation for two
hours at room temperature with streptavidin-ALPH conju-
gate (Dako Corp., Carpenteria, CA, USA) at 1:1000 dilu-
tion. Plates were then washed two times with PBST and
twice with PBS. The NBT/BCIP substrate (50% NBT buffer,
33% stock NBT, and 17% stock BCIP) was added and left
for 15–30 minutes. The reaction was stopped by rinsing
with tap water, and the plates were allowed to dry over-
night. The following coating antibodies were used for IL-
2, IL-4, IL-5 and IFN-γ, respectively: JES6–1A12 (2 µg/ml),
BVD4-1D11 (4 µg/ml), TRFK5 (5 µg/ml) and R46A2 (2
µg/ml). The detection antibody concentrations were as
follows: JES6-5H4-biotin (1 µg/ml), BVD4-24G2-biotin
(1 µg/ml), TRFK4-biotin (1 µg/ml) and XMG1.2-biotin (2
µg/ml). All antibodies were purchased from BD-Pharmin-
gen, San Diego, CA.
Computer-assisted ELISPOT image analysis
The image analysis was performed using a Series 3B
ImmunoSpot®Image Analyzer (Cellular Technology,
Ltd.). Digitized images were analyzed for the presence of
areas in which color density exceeded background by a
factor set on the basis of the comparison of control wells
(containing T cells and antigen-presenting cells (APC)
without antigen) and experimental wells containing colla-
gen as the antigen. After separating spots that touch or
partially overlap, additional criteria of spot size and circu-
larity were applied to gate out speckles and noise caused
by spontaneous substrate precipitation, nonspecific anti-
body binding, and "ELISA effects". Objects that did not
meet these criteria were ignored and areas that met them
were recognized as spots, counted, and highlighted.
Measurement of specific serum antibodies
Standard ELISA assays were conducted to determine a
humoral-mediated immune response. These assays meas-
ured the titers of collagen-specific antibodies in the sera of
the mice, specifically IgG1, IgG2a, total IgG and IgM. After
blood was obtained from the tail vein of the mouse, the
cells were pelleted by centrifugation and the serum was
collected. Plates (Nunc Immunoplate, Fisher Scientific,
Pittsburgh, PA, USA) were coated with bovine type II col-
lagen (10 µg/ml) or human collagen (5 µg/ml) diluted in
bicarbonate buffer overnight at 4°C, then blocked for one
to two hours with 0.1% gelatin in PBST. The test serumPage 4 of 10
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antibody was detected by biotinylated anti-mouse immu-
noglobulin. Rat anti-mouse IgG from Zymed (San Fran-
cisco, CA, USA) was used to detect total Ig; the isotype-
specific antibodies used to detect IgG1, IgG2a, and IgM
were also purchased from Zymed. Tertiary antibody,
streptavidin-alkaline phosphatase was purchased from
Dako (Carpenteria, CA, USA) and p-Nierophenyl phos-
phate disodium salt (PNPP) was used for the develop-
ment of the colorimetric reaction.
Histological analysis
After removal from the implantation site, each graft was
placed in 10% buffered formalin solution for a minimum
of seven days. The retrieved specimens were then decalci-
fied, embedded in paraffin, sectioned and stained with
hematoxylin and eosin. All sections were reviewed by a
blinded pathologist.
Statistical analysis
Statistical analysis was conducted on the cytokine results.
Tests used to determine statistical significance included
the two-tailed student's t test and the Mann Whitney Rank




The average number of collagen-specific cytokine-produc-
ing T cells per million spleen cells at four weeks post-
implantation are shown in Figure 1. In CFA:collagen-
immunized positive control mice, the IFN-γ and IL-2
responses were significantly greater than those engaged in
mice receiving photooxidized grafts after four weeks (p <
0.05). The CFA:collagen immunization generated a signif-
icantly greater IL-2 response compared to the unprocessed
bovine graft. Regarding the IFA:collagen-immunized pos-
itive controls, the cytokine response to the positive con-
trols was not significantly different than that induced by
either the unprocessed or photooxidized grafts. The pres-
ence of neither the unprocessed nor the photooxidized
grafts induced a significant increase in cytokine produc-
tion versus sham mice. The IL-2 response to photooxi-
dized grafts was significantly less than the same response
to the unprocessed grafts. There was no significant pro-
duction of IL-4 or IL-5 by any mice.
ELISA testing indicated that, after four weeks, bovine col-
lagen-specific antibodies were not induced in the sham-
operated mice. There was no elevation of bovine collagen-
specific antibodies in response to either unprocessed or
photooxidized bovine osteochondral grafts.
The number of collagen-specific cytokine-producing T
cells per million spleen cells at twelve weeks post-implan-
tation in mice that received bovine osteochondral grafts
are shown in Figure 2. Collagen-specific T cells were
present in significantly higher frequencies in the CFA:col-
lagen-immunized positive controls than in mice that have
received unprocessed and photooxidized grafts (p < 0.05).
There was no significant difference between the cytokine
responses to collagen in the IFA:collagen-immunized con-
trol mice and the mice that received photooxidized grafts.
The IFN-γ response to the unprocessed grafts, however,
was significantly greater than the response in the IFA:col-
lagen-immunized controls. The photooxidized grafts did
not induce a significant T cell response to collagen over
what was seen in sham treated control mice, while the
unprocessed graft produced an elevated IL-4 response ver-
sus the negative controls. The IFN-γ response to the pho-
tooxidized grafts was significantly less than the response
to the unprocessed grafts. There was no significant IL-5
elevation in any of the mice.
Cytokine response to bovine collagen (4 weeks)Figure 1
Cytokine response to bovine collagen (4 weeks). The 
average number of cytokine-producing T cells per million 
spleen cells in response to a challenge from bovine collagen 
and osteochondral grafts at four weeks.
Cytokine response to bovine collagen (12 weeks)Figure 2
Cytokine response to bovine collagen (12 weeks). The 
average number of cytokine-producing T cells per million 
spleen cells in response to a challenge from bovine collagen 
and osteochondral grafts at twelve weeks.Page 5 of 10
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ment bovine collagen-specific IgG and IgM antibodies
were not produced in the sham-operated mice. The
unprocessed bovine grafts did not induce production of
bovine collagen-specific IgG, IgG1 and IgG2a antibodies.
Specific IgM antibodies, however, were produced in
response to the unprocessed material. Similarly, only
bovine collagen-specific IgM antibodies were produced
after twelve weeks exposure to photooxidized grafts.
Human grafts
The average number of collagen-specific cytokine-produc-
ing T cells per million spleen cells at four weeks post-
implantation in mice that received human osteochondral
grafts is shown in Figure 3. The IL-4 response induced by
CFA:collagen immunization was significantly greater than
that induced by either the unprocessed or photooxidized
grafts (p < 0.05). In addition, the IFN-γ response induced
by the unprocessed grafts was significantly less than that
induced in response to the CFA:collagen-immunized pos-
itive controls In IFA:collagen-immunized controls, the
collagen-induced IL-2 production was significantly greater
than that induced by the photooxidized grafts. Also the
collagen-induced IL-4 production in the IFA:collagen-
immunized control mice was significantly greater than
that in the mice that received unprocessed grafts. Neither
the unprocessed nor photooxidized grafts induced a sig-
nificant T cell response versus the sham mice. There was
no significant difference between the cytokine responses
induced by the unprocessed and photooxidized grafts.
Also, there was no significant IL-5 elevation in any of the
mice.
ELISA testing showed, after four weeks, production of
human collagen-specific IgG antibodies was not induced
in the sham-operated negative control mice, however,
these mice demonstrated elevated levels of IgM antibod-
ies. Similarly, there was not an increased production of
human collagen-specific IgG antibodies in response to
unprocessed human grafts, but there was an elevated spe-
cific IgM response. In response to the photooxidized
human grafts, there was no elevated human collagen-spe-
cific total IgG and IgG2a production, while a weak IgG1
response was observed in two of eight mice. There was ele-
vated IgM production in response to the photooxidized
grafts.
The average number of collagen-specific cytokine-produc-
ing T cells per million spleen cells at twelve weeks post-
implantation in mice that received human osteochondral
grafts are shown in Figure 4. The numbers of collagen-spe-
cific IFN-γ, IL-2 and IL-4 producing T cells were signifi-
cantly higher in CFA:collagen-immunized mice than in
mice that received unprocessed or photooxidized grafts (p
< 0.05). IL-2 and IL-4 production was also significantly
greater for the IFA:collagen-immunized control mice,
compared to mice receiving either an unprocessed or a
photooxidized graft. The T cell response to the unproc-
essed and photooxidized grafts was not significantly dif-
ferent than that generated by the negative control mice.
There was no significant difference between the cytokine
response induced by the unprocessed grafts and that
induced by the photooxidized grafts. IL-5 production was
negligible in all mice.
ELISA testing showed that, after twelve weeks, there was
no increased production of human collagen-specific IgG
antibodies in sham-operated mice, but there were ele-
vated IgM titers in these mice. There were no elevated
serum levels of collagen-specific IgG antibodies in mice
grafted with unprocessed human cartilage, while IgM tit-
ers were high in these mice. With respect to the photooxi-
dized human grafts, two of the seven mice showed high
specific IgG1 titers, and one additional mouse showed an
elevated IgG1 level. These grafts also induced high titers of
Cytokine response to human collagen (4 weeks)Figure 3
Cytokine response to human collagen (4 weeks). The 
average number of cytokine-producing T cells per million 
spleen cells in response to a challenge from human collagen 
and osteochondral grafts at four weeks.
Cytokine response to human collagen (12 weeks)Figure 4
Cytokine response to human collagen (12 weeks). 
The average number of cytokine-producing T cells per mil-
lion spleen cells in response to a challenge from human colla-
gen and osteochondral grafts at twelve weeks.Page 6 of 10
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levels of IgG2a in another mouse. There were elevated tit-
ers of collagen-specific IgM in all mice implanted with the
photooxidized graft.
Histological findings
The histological findings were similar for bovine and
human grafts, regardless of whether the grafts were
unprocessed or photooxidized. All grafts showed some
degree of fibrous encapsulation. The degree and extent of
encapsulation varied and showed no consistent trend
related to graft type, processing or duration of implanta-
tion. The cartilage and bone revealed the absence of
chondrocytes and osteocytes, respectively. All grafts dem-
onstrated some degree of inflammation ranging from
mild to moderate and can best be described as mixed in
character, with evidence of both acute and chronic inflam-
matory processes. The inflammation was observed to
begin at the periphery of the implants at four weeks, with
extension of an inflammatory or fibroinflammatory infil-
trate into the medullary spaces at twelve weeks.
Discussion
This study was conducted to assess the immunogenicity of
osteochondral tissue grafts. The collagen-sensitive murine
model used in this study was selected along with a subcu-
taneous site for implantation to ensure a "worst case sce-
nario" situation. The grafts consist of bone and cartilage,
and collagen is a main protein constituent of the
implanted material. When immunized with type II colla-
gen, the DBA/1LacJ mice develop a strong immune
response to collagen which results in severe autoimmune
arthritis. [35] In this current experimental system, such
immunizations with collagen were used as the positive
control, measuring the magnitude of the ensuing T- and B-
cell responses. Subcutaneous antigen encounter favors the
induction of an immune response because of the high
density of dendritic cells in the skin – skin grafts therefore
can be expected to be more immunogenic than joint
implants.
The frequencies of collagen-specific T cells as identified by
their cytokine signature in ELISPOT assays showed that
the implantation of bovine photooxidized osteochondral
grafts did not induce detectable T cell immunity within
four or twelve weeks. While no response was detected in
mice that received the unprocessed graft after four weeks,
a slight elevation in IL-4 after twelve weeks in comparison
to the sham-operated mice suggests a possible weak cellu-
lar Th2 response in these mice. In certain instances at both
time periods, the unprocessed grafts were moderately
more active compared to the photooxidized grafts. The
fact that none of the mice, including the positive controls,
elicited an elevated IL-5 response after twelve weeks sug-
gests that this arm of the Th2 response may not be partic-
ipating in the response to bovine collagen.
Bovine collagen-specific total IgG, IgG1 and IgG2a anti-
bodies were not induced by the unprocessed or photoox-
idized bovine osteochondral grafts at either four or twelve
weeks. By twelve weeks, however, specific IgM antibodies
emerged in all of the mice receiving either type of graft.
IgM antibodies did not appear at either time period in the
mice receiving a sham operation, thus suggesting that
mice that received the bovine grafts displayed a weak,
delayed IgM antibody response. The production of IgM
antibodies does not require T cell help. The fact that these
collagen-specific IgM antibodies appeared late, and in the
absence of T-cell dependent IgG antibodies, along with
the lack of detectable T cell activity suggest such a T cell
independent weak IgM B cell response.
Measurements of collagen-induced cytokine production
in mice implanted with human osteochondral grafts con-
firmed that neither the unprocessed nor the photooxi-
dized samples induced a significant T cell response after
four or twelve weeks. This would suggest that, with respect
to adaptive T cell immunity, either implant type would be
suitable for transplantation.
None of the mice grafted with unprocessed human osteo-
chondral grafts generated human collagen-specific total
IgG, IgG1 or IgG2a antibodies at either time period. How-
ever, a weak IgG1 response was generated by four weeks
after implantation with the photooxidized human graft,
with a further increase in IgG1 levels at twelve weeks. In
addition, one mouse exhibited high IgG2a production
after twelve weeks. These antibodies are dependent on
antigen-specific T cell help suggesting that T cell immunity
was induced. While IgG1 antibodies are present in Th1
and Th2 immunity, B cell isotype switching to IgG2a
requires IFN-γ and thus is linked to Th1 immunity. Strik-
ingly, these mice showed "natural IgM" antibodies to col-
lagen, that is, even untreated "naïve" mice had collagen-
specific IgM antibodies in their serum. Such "natural anti-
bodies" are typically induced by environmental stimuli,
such as the bacterial flora; the blood group antibodies
being the best known examples. It is likely that these "nat-
ural" anti-human collagen antibodies in mice are directed
against glycosylation differences between the two species.
The appearance of graft-specific antibodies clearly shows
that the indirect pathway of graft rejection has been
engaged. This mechanism, first introduced by Benichou et
al. [36], entails the sensitization of recipient T cells to
processed antigens of donor origin that are expressed on
the surface of recipient antigen-presenting cells. Accompa-
nying the T cell response, a B cell response can also be
engaged, resulting in the production of antibodiesPage 7 of 10
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result in graft rejection even in the absence of the classical
direct pathway (in which T cells react when exposed to
allo- or xeno-peptide complexes that are expressed on the
surface of donor antigen-presenting cells), however, rejec-
tion resulting from the indirect pathway is typically pro-
longed. [38] As with the induction of any T cell response,
it is required that the antigen-presenting cells of the innate
immune system are in an activated state in order to prime
the T cells that mediate indirect graft rejection. The proc-
essed allo- or xeno-antigen can then be linked with
enhanced costimulation, resulting in rejection. In the
absence of such activation-dependent costimulation, tol-
erance develops. By measuring the activation of the cells
of the innate immune system, information on the engage-
ment of costimulation can be provided.
The results from this study and a previous study con-
ducted by Hetherington et al. [34] provide an overall anal-
ysis of both the innate and the adaptive immune
responses to photooxidized osteochondral xenografts.
The findings are summarized in Table 3. As can be seen,
there is a considerable reduction in the innate immune
response after processing the osteochondral grafts. While
the adaptive T cell response is negligible in both unproc-
essed and photooxidized implants, the humoral response
to both graft types needs to be addressed to determine
why a response, particularly IgM, is induced.
The histologic appearance of the explanted grafts, which
showed fibrous encapsulation and infiltration of acute
and chronic inflammatory components into the graft
itself, is inconsistent with results seen in previous works,
in which the grafts were inserted into bone as opposed to
subcutaneous implantation in this study. [29-32] A previ-
ous study conducted by three of the authors (JSK-C, VJH
and DN) in which osteochondral xenografts were
implanted into the patellar groove of rabbits demon-
strated a nonspecific inflammatory response with the
implants being well tolerated and, in some instances, the
graft bone was in the initial stages of incorporation into
the host bone. [29] The inflammation observed in this
study appeared to be more intense and may be accounted
for by a difference in implantation site, with the subcuta-
neous location favoring immune sensitization of the host.
The use of a collagen-sensitive mouse may also affect the
response to the graft itself. To clarify the mechanism
underlying the inflammatory response, two of the authors
(JSK-C and VJH) implanted two photooxidized bovine
osteochondral grafts subcutaneously into immunodefi-
cient Rag-1 gene knock out mice (B6.129S7-Rag1tm1Mom/J,
Jackson Laboratory, Bar Harbor, ME, USA). These mice are
deficient in mature B cells or T cells. The mice were sacri-
ficed four weeks after grafting and the implants were sub-
jected to histological analysis. The inflammatory reaction
to the grafts seen in these immunodeficient mice was sim-
ilar in quality and magnitude to that of the collagen-sen-
sitive mice. This outcome suggests that the inflammatory
response observed in the grafts results from a response of
the innate immune system and that the IgM antibodies
seen in the immune competent mice did not play a detect-
able role in intensifying it.
It should be noted that the grafts were tested in the same
form as would be used clinically. The cylindrical graft con-
sisted of a cartilage layer with underlying bone. However,
the location of implantation was not clinically relevant.
As indicated above, the subcutaneous implantation site
was chosen in order to achieve a stronger immunological
response. Previous studies have also indicated that, histo-
logically, photooxidized grafts are better accepted by the
host, both in non-weight-bearing [29] and weight-bearing
[30-32] areas of the joint. The next logical step in this cur-
rent research is to evaluate the immune response to the
photooxidized implant when placed in a clinically-rele-
vant weight-bearing joint.
Conclusion
Both bovine and human cartilage grafts showed weak, but
clear immunogenicity in the DBA/1LacJ mice. Regarding T
cell immunity, the unprocessed bovine grafts were slightly
more immunogenic than photooxidized bovine grafts,
unprocessed human grafts and photooxidized human
grafts. With respect to antibodies, bovine grafts were less
immunogenic than human grafts, but both photooxi-
dized and unprocessed bovine grafts induced a late IgM
response. Bovine collagen-specific IgG antibodies were
not induced by these grafts. In contrast, photooxidized
Table 3: Summary of immunology studies on photooxidized osteochondral xenografts
Unprocessed Photooxidized
Macrophages, cells of the innate immune system (ref. 34) ++++++ +
Adaptive T cell response to bovine grafts (cellular) + -
Adaptive T cell response to human grafts (cellular) - -
Adaptive B cell response to bovine grafts (humoral) – IgG1, IgG2a, IgG - -
Adaptive B cell response to human grafts (humoral) – IgG1, IgG2a, IgG - +
Adaptive B cell response to bovine and human grafts (humoral) – IgM ++ ++Page 8 of 10
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IgG1 and IgG2a antibodies.
In conclusion, the data clearly show that immunogenic
material is still contained in the graft, and the adaptive
immunogenicity is not reduced by photooxidation, as
suggested by the emergence of antibodies, primarily IgM.
Photooxidation of the osteochondral grafts is still impor-
tant, however, in order to retain the mechanical integrity
of the cartilage, thus allowing for immediate joint resur-
facing. The next phase of the study is to evaluate the
immune reactions when the graft is placed into a weight-
bearing joint. In addition, evaluation of the photooxi-
dized material for the presence of viral or other residual
infectious materials, such as α-galactase, should be con-
ducted. It may also be helpful to evaluate the innate
immune response to human photooxidized osteochon-
dral grafts, using peripheral blood mononuclear cells
from healthy human donors, as human material was not
tested in the immunological analysis of the innate
immune response conducted previously by the authors.
[34]
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